Current and future cancer staging after neoadjuvant treatment for solid tumors

Area of Science:

• Oncology
• Cancer Registry Science
• Clinical Staging

Background:

• Traditional cancer registries capture pre-treatment and post-surgical staging.
• Neoadjuvant therapy (NAT) is increasingly used, necessitating new staging methods.
• Current registries lack standardized data collection for post-NAT staging.

Purpose of the Study:

• To highlight the importance of collecting staging data after neoadjuvant therapy (NAT).
• To advocate for standardized data collection of post-NAT staging (y stage) and clinical response (yc).
• To review pathological and imaging changes post-NAT for accurate staging.

Main Methods:

• Review of pathological and imaging changes after NAT in breast, rectal, and esophageal cancers.
• Analysis of current cancer registry practices regarding NAT data collection.
• Discussion of the implications of standardized y stage and yc data.

Main Results:

• Cancer registries currently only partially collect y stage data.
• Clinical response data (yc) to NAT is not collected or recorded in a standardized manner.
• Inconsistent data collection hinders assessment of NAT effectiveness.

Conclusions:

• Standardized collection of y stage and yc data is essential for evaluating NAT.
• Accurate staging post-NAT is critical for understanding treatment response and patient outcomes.
• Improved data collection will support evidence-based practice in oncology.